|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
EP0092918B1
(en)
|
1982-04-22 |
1988-10-19 |
Imperial Chemical Industries Plc |
Continuous release formulations
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
WO1988009344A1
(en)
|
1987-05-21 |
1988-12-01 |
Creative Biomolecules, Inc. |
Targeted multifunctional proteins
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
AU6430190A
(en)
|
1989-10-10 |
1991-05-16 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP0550436A1
(en)
|
1989-11-06 |
1993-07-14 |
Alkermes Controlled Therapeutics, Inc. |
Protein microspheres and methods of using them
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
WO1992009690A2
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
|
WO1992010591A1
(en)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
EP1136556B1
(en)
|
1991-11-25 |
2005-06-08 |
Enzon, Inc. |
Method of producing multivalent antigen-binding proteins
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
WO1993011794A1
(en)
|
1991-12-13 |
1993-06-24 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
NZ292124A
(en)
|
1994-07-29 |
1998-10-28 |
Smithkline Beecham Plc |
Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
|
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
|
DE69630514D1
(de)
|
1995-01-05 |
2003-12-04 |
Univ Michigan |
Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
|
|
EP1658772A3
(en)
|
1995-01-17 |
2007-01-17 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO1997007788A2
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2462113C
(en)
|
2001-10-01 |
2013-01-29 |
Dyax Corp. |
Multi-chain eukaryotic display vectors and uses thereof
|
|
US20040005709A1
(en)
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US8603930B2
(en)
|
2005-10-07 |
2013-12-10 |
Sulzer Metco (Us), Inc. |
High-purity fused and crushed zirconia alloy powder and method of producing same
|
|
BRPI0807952A2
(pt)
|
2007-02-20 |
2014-06-10 |
Anaptysbio Inc |
Sistemas de hipermutação somática
|
|
JP5547656B2
(ja)
|
2008-01-15 |
2014-07-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Ｃｄ４７によって媒介される食作用を操作するための方法
|
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
|
SI2477648T1
(sl)
|
2009-09-15 |
2022-09-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Sinergijska terapija proti CD47 za krvne rake
|
|
WO2012059561A1
(en)
*
|
2010-11-03 |
2012-05-10 |
Argen-X-Bv |
Anti c-met antibodies
|
|
WO2012088309A1
(en)
|
2010-12-21 |
2012-06-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
|
|
US9574002B2
(en)
*
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
US20140242095A1
(en)
|
2011-10-19 |
2014-08-28 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
|
CA2900256C
(en)
|
2013-02-05 |
2023-03-21 |
Kim J. HASENKRUG |
Cd47 targeted therapies for the treatment of infectious disease
|
|
JP6426693B2
(ja)
|
2013-03-15 |
2018-11-21 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
抗ｃｄ４７薬の処理上有効量を達成するための方法
|
|
ES2898627T3
(es)
|
2013-04-29 |
2022-03-08 |
Univ Leland Stanford Junior |
Uso de agentes anti-CD47 para mejorar la inmunización
|
|
WO2014186761A2
(en)
|
2013-05-17 |
2014-11-20 |
The Board Of Trustes Of The Leland Stanford Junior University |
Methods for determining responsiveness to an anti-cd47 agent
|
|
US9667770B2
(en)
|
2013-07-17 |
2017-05-30 |
Flypsi, Inc. |
Telephone network system and method
|
|
EP3046627B1
(en)
|
2013-09-18 |
2019-10-23 |
The Board of Trustees of the Leland Stanford Junior University |
Modulation of efferocytosis pathways for treatment of atherosclerotic disease
|
|
WO2015105995A2
(en)
|
2014-01-08 |
2015-07-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted therapy for small cell lung cancer
|
|
JP6606505B2
(ja)
|
2014-03-11 |
2019-11-13 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
|
|
WO2016022971A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Sirp alpha-antibody fusion proteins
|
|
SI3656869T2
(sl)
|
2014-08-26 |
2025-06-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Vsaditev matičnih celic s kombinacijo sredstva, ki cilja matične celice in modulacija imunoregulatornega signaliziranja
|
|
CA2958898A1
(en)
|
2014-09-15 |
2016-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
US10550187B2
(en)
|
2014-10-24 |
2020-02-04 |
Incept, Llc |
Extra luminal scaffold
|
|
CA2959821C
(en)
|
2014-10-24 |
2024-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
GB201503387D0
(en)
*
|
2015-02-27 |
2015-04-15 |
ALERE TECHNOLOGIES GmbH |
Anti-carbapenem antibodies and uses thereof
|
|
EP4019040A1
(en)
|
2015-01-21 |
2022-06-29 |
The Board of Trustees of the Leland Stanford Junior University |
Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
|
|
ES2838925T3
(es)
|
2015-02-27 |
2021-07-02 |
Univ Leland Stanford Junior |
Terapia de combinación para el tratamiento de la ateroesclerosis
|
|
CA2978892A1
(en)
*
|
2015-03-06 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
JP6999421B2
(ja)
*
|
2015-04-07 |
2022-02-04 |
アレクトル エルエルシー |
抗ソルチリン抗体及びその使用方法
|
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
|
SI3328419T1
(sl)
|
2015-07-30 |
2021-11-30 |
Macrogenics, Inc. |
PD-1-vezavne molekule in postopki uporabe le-teh
|
|
SG10202101909RA
(en)
|
2015-08-07 |
2021-04-29 |
Alx Oncology Inc |
Constructs having a sirp-alpha domain or variant thereof
|
|
SI3341015T2
(sl)
|
2015-08-26 |
2024-03-29 |
The Board Of Trustees Of The Leland Stanford, Junior University |
Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom
|
|
EP4186927B1
(en)
|
2015-10-21 |
2025-04-23 |
Ose Immunotherapeutics |
Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
|
|
EP3371301A4
(en)
|
2015-11-04 |
2019-06-26 |
Fate Therapeutics, Inc. |
METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
|
|
EP3165536A1
(en)
|
2015-11-09 |
2017-05-10 |
Ludwig-Maximilians-Universität München |
Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
|
|
US10946042B2
(en)
|
2015-12-01 |
2021-03-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for selective phagocytosis of human cancer cells
|
|
SG11201805649UA
(en)
|
2016-01-08 |
2018-07-30 |
Aimm Therapeutics Bv |
Therapeutic anti-cd9 antibody
|
|
KR102833922B1
(ko)
|
2016-01-21 |
2025-07-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
면역조절제의 조합물에 의한 암의 치료
|
|
WO2017152132A1
(en)
|
2016-03-04 |
2017-09-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of identifying and treating immune checkpoint inhibitor-responsive neoplasms
|
|
US20190077856A1
(en)
|
2016-03-15 |
2019-03-14 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
|
EP3995139A1
(en)
|
2016-04-10 |
2022-05-11 |
Georgia State University Research Foundation, Inc. |
Composition for use in treating cancer
|
|
US11110152B2
(en)
|
2016-04-11 |
2021-09-07 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating and preventing lung disease
|
|
EP4438626A3
(en)
|
2016-04-14 |
2024-12-04 |
OSE Immunotherapeutics |
New anti-sirpa antibodies and their therapeutic applications
|
|
CN117695387A
(zh)
|
2016-04-15 |
2024-03-15 |
小利兰·斯坦福大学托管委员会 |
用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
|
|
WO2017184553A1
(en)
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
|
US10934355B2
(en)
|
2016-04-29 |
2021-03-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for the prevention and treatment of surgical adhesions
|
|
EP3458094A4
(en)
|
2016-05-19 |
2020-01-08 |
Adaerata, Limited Partnership |
METHOD FOR PREVENTING OR TREATING SLAMF7-POSITIVE AND SLAMF7-NEGATIVE CANCER
|
|
CN109475627B
(zh)
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018005775A1
(en)
|
2016-06-29 |
2018-01-04 |
Memorial Sloan-Kettering Cancer Center |
Cd47 blockade enhances therapeutic activity of antibodies to low density cancer epitopes
|
|
US20190153095A1
(en)
|
2016-07-05 |
2019-05-23 |
National University Corporation Kobe University |
Antitumor Agent
|
|
WO2018026600A1
(en)
*
|
2016-08-03 |
2018-02-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
|
|
WO2018037091A1
(en)
|
2016-08-24 |
2018-03-01 |
Hi-Stem Ggmbh |
Methods for the identification and isolation of hematopoietic stem and progenitor cells
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
EP3411071A4
(en)
*
|
2016-10-20 |
2019-08-28 |
I-Mab |
NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF
|
|
US11446315B2
(en)
|
2016-11-03 |
2022-09-20 |
Pf Argentum Ip Holdings Llc |
Enhancement of CD47 blockade therapy by proteasome inhibitors
|
|
CA3044684A1
(en)
*
|
2016-12-09 |
2018-06-14 |
Alector Llc |
Anti-sirp-alpha antibodies and methods of use thereof
|
|
EA201891882A1
(ru)
*
|
2017-02-17 |
2019-07-31 |
Осе Иммьюнотерапьютикс |
НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ
|
|
CN110300764A
(zh)
|
2017-02-17 |
2019-10-01 |
Ose免疫疗法 |
抗SIRPg抗体的新用途
|
|
EP3589368A4
(en)
|
2017-02-28 |
2021-03-24 |
The Board of Trustees of the Leland Stanford Junior University |
ANTIFIBROTIC ACTIVITY OF CD47 BLOCKING
|
|
WO2018165015A1
(en)
|
2017-03-09 |
2018-09-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of pediatric brain tumors with targeting of cd47 pathway
|
|
US11873486B2
(en)
|
2017-03-31 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
|
|
CN118267470A
(zh)
|
2017-04-13 |
2024-07-02 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
|
PL3625259T3
(pl)
|
2017-05-16 |
2024-08-12 |
Byondis B.V. |
Przeciwciała anty-sirpalfa
|
|
WO2019014663A1
(en)
|
2017-07-14 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
MODULATION OF BIOMARKERS TO INCREASE ANTI-TUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF CANCER IMMUNOTHERAPY
|
|
WO2019014664A1
(en)
|
2017-07-14 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
|
|
US11740242B2
(en)
|
2017-07-14 |
2023-08-29 |
Dana-Farber Cancer Institute, Inc. |
Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
|
|
WO2019018813A1
(en)
|
2017-07-21 |
2019-01-24 |
Varian Medical Systems, Inc. |
METHODS OF USING ULTRA HIGH DOSE RATE RADIATION AND THERAPEUTIC AGENTS
|
|
FI3658141T3
(fi)
|
2017-07-24 |
2023-03-02 |
|
Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella
|
|
CN111448210B
(zh)
|
2017-07-26 |
2024-05-14 |
四十七公司 |
抗SIRP-α抗体及相关方法
|
|
JP7395471B2
(ja)
|
2017-10-13 |
2023-12-11 |
オーセ イミュノセラピューティクス |
改変抗ＳＩＲＰａ抗体及びその使用
|
|
CA3080640C
(en)
|
2017-11-06 |
2024-04-09 |
Trillium Therapeutics Inc. |
Cd47 blockade with radiation therapy
|
|
WO2019090355A1
(en)
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
EP3723770A4
(en)
|
2017-12-13 |
2021-11-24 |
North Carolina State University |
COMPOSITIONS INCLUDING CHEMOTHERAPEUTIC AGENTS AND CHECKPOINT INHIBITORS AND METHODS OF USE
|
|
GB201800649D0
(en)
|
2018-01-16 |
2018-02-28 |
Argenx Bvba |
CD70 Combination Therapy
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
CN108484774B
(zh)
*
|
2018-03-09 |
2021-11-05 |
上海高菲生物科技有限公司 |
一种SIRPα融合蛋白及其制备方法和用途
|